Idarucizumab for Intravenous Thrombolysis and Endovascular Thrombectomy in Acute Stroke: A Case Report
- 1 March 2020
- journal article
- research article
- Published by Elsevier in The Journal of Emergency Medicine
- Vol. 58 (3) , e113-e116
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Ciraparantag Safely and Effectively Reverses Apixaban and Rivaroxaban in Age-Matched Healthy Volunteers As Measured By Whole Blood Clotting TimeBlood, 2018
- Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non–Vitamin K Antagonist Oral Anticoagulants Preceding StrokeStroke, 2018
- Andexanet Alfa: First Global ApprovalDrugs, 2018
- 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke AssociationStroke, 2018
- Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion ImagingNew England Journal of Medicine, 2018
- Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and InfarctNew England Journal of Medicine, 2018
- Mechanical Thrombectomy Outcomes With and Without Intravenous Thrombolysis in Stroke PatientsStroke, 2017
- Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatranThrombosis and Haemostasis, 2015
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014
- A specific antidote for dabigatran: functional and structural characterizationBlood, 2013